Shares of Caladrius Biosciences Inc (NASDAQ:CLBS) have received a consensus rating of “Hold” from the six brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $10.42.
CLBS has been the subject of a number of research analyst reports. Zacks Investment Research cut Caladrius Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, February 1st. Dawson James restated a “buy” rating on shares of Caladrius Biosciences in a research note on Wednesday, February 27th. HC Wainwright restated a “buy” rating and issued a $18.50 target price on shares of Caladrius Biosciences in a research note on Thursday, January 24th. ValuEngine cut Caladrius Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, WBB Securities initiated coverage on Caladrius Biosciences in a research report on Tuesday, May 14th. They set a “speculative buy” rating and a $6.75 price objective for the company.
A number of hedge funds have recently bought and sold shares of the stock. Summit Trail Advisors LLC bought a new position in Caladrius Biosciences during the 1st quarter valued at approximately $64,000. Morgan Stanley increased its position in Caladrius Biosciences by 218.6% during the 1st quarter. Morgan Stanley now owns 6,996 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 4,800 shares in the last quarter. Renaissance Technologies LLC increased its position in Caladrius Biosciences by 6.9% during the 1st quarter. Renaissance Technologies LLC now owns 315,348 shares of the biotechnology company’s stock valued at $1,142,000 after buying an additional 20,253 shares in the last quarter. Wesbanco Bank Inc. bought a new position in Caladrius Biosciences during the 1st quarter valued at approximately $36,000. Finally, Vanguard Group Inc increased its position in Caladrius Biosciences by 2.9% during the 3rd quarter. Vanguard Group Inc now owns 202,568 shares of the biotechnology company’s stock valued at $1,196,000 after buying an additional 5,700 shares in the last quarter. 7.10% of the stock is owned by institutional investors.
Caladrius Biosciences (NASDAQ:CLBS) last released its earnings results on Thursday, May 9th. The biotechnology company reported ($0.44) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.05). As a group, research analysts expect that Caladrius Biosciences will post -1.65 earnings per share for the current fiscal year.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Recommended Story: Book Value Per Share in Stock Trading
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.